<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7049676/results/search/country/results.xml">
  <result pre="continues to contribute to the burden of liver disease in" exact="the United States," post="causing chronic hepatitis, cirrhosis and decompensated disease, liver cancer,"/>
  <result pre="to contribute to the burden of liver disease in the" exact="United States," post="causing chronic hepatitis, cirrhosis and decompensated disease, liver cancer,"/>
  <result pre="remains one of the most prevalent chronic liver diseases in" exact="the United States" post="and beyond, but the infected population is shifting toward"/>
  <result pre="one of the most prevalent chronic liver diseases in the" exact="United States" post="and beyond, but the infected population is shifting toward"/>
  <result pre="from 1.3% in the Americas to 2.9% in Africa.4 In" exact="the United States," post="an epidemiological study of the National Health and Nutrition"/>
  <result pre="1.3% in the Americas to 2.9% in Africa.4 In the" exact="United States," post="an epidemiological study of the National Health and Nutrition"/>
  <result pre="million people with chronic HCV in the United States.6 In" exact="the United States," post="although the disease burden from HCV is decreasing, the"/>
  <result pre="people with chronic HCV in the United States.6 In the" exact="United States," post="although the disease burden from HCV is decreasing, the"/>
  <result pre="identification, yet effective screening has persistently been a challenge in" exact="the United States." post="A recent study of screening strategies identified that reflex"/>
  <result pre="yet effective screening has persistently been a challenge in the" exact="United States." post="A recent study of screening strategies identified that reflex"/>
  <result pre="the exception of pregnant women AASLD, Infectious Disease Society of" exact="America" post="(IDSA)13 2019 Risk behavior, risk exposure, or other conditions*"/>
  <result pre="between 0.20% in the Americas to 22.38% in Africa. In" exact="the United States," post="HBsAg seroprevalence was 0.27%, corresponding to 843,724 individuals with"/>
  <result pre="0.20% in the Americas to 22.38% in Africa. In the" exact="United States," post="HBsAg seroprevalence was 0.27%, corresponding to 843,724 individuals with"/>
  <result pre="nucleotide reverse‐transcriptase inhibitor and prodrug of tenofovir, was approved in" exact="the United States" post="in 2016 and has emerged as one effective first‐line"/>
  <result pre="reverse‐transcriptase inhibitor and prodrug of tenofovir, was approved in the" exact="United States" post="in 2016 and has emerged as one effective first‐line"/>
  <result pre="et al. Estimating prevalence of hepatitis C virus infection in" exact="the United States," post="2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for Disease Control and Prevention"/>
  <result pre="al. Estimating prevalence of hepatitis C virus infection in the" exact="United States," post="2013‐2016. Hepatology2019;69:1020‐1031.30398671 6collab: Centers for Disease Control and Prevention"/>
  <result pre="MishraA, RafiqN, et al. Epidemiology of chronic liver diseases in" exact="the USA" post="in the past three decades. Gut2019 Jul 31. 10.1136/gutjnl-2019-318813."/>
  <result pre="KabiriM, ChungRT, HurC, et al. Hepatitis C disease burden in" exact="the United States" post="in the era of oral direct‐acting antivirals. Hepatology2016;64:1442‐1450.27015107 12ChapkoMK,"/>
  <result pre="ChungRT, HurC, et al. Hepatitis C disease burden in the" exact="United States" post="in the era of oral direct‐acting antivirals. Hepatology2016;64:1442‐1450.27015107 12ChapkoMK,"/>
  <result pre="targets. J Hepatol2019;70:e748. 28HolmbergSD, SpradlingPR, MoormanAC, DennistonMM. Hepatitis C in" exact="the United States." post="N Engl J Med2013;368:1859‐1861.23675657 29LinasBP, BarterDM, LeffJA, AssoumouSA, SalomonJA,"/>
  <result pre="J Hepatol2019;70:e748. 28HolmbergSD, SpradlingPR, MoormanAC, DennistonMM. Hepatitis C in the" exact="United States." post="N Engl J Med2013;368:1859‐1861.23675657 29LinasBP, BarterDM, LeffJA, AssoumouSA, SalomonJA,"/>
  <result pre="of the Hepatitis C Care Cascade: A Real‐World Analysis from" exact="the United States." post="Vienna, Austria: European Association for the Study of the"/>
  <result pre="the Hepatitis C Care Cascade: A Real‐World Analysis from the" exact="United States." post="Vienna, Austria: European Association for the Study of the"/>
  <result pre="etiology of liver disease among adults awaiting liver transplantation in" exact="the United States." post="Gastroenterology2015;148:547‐555.25461851 40YounossiZ, AnsteeQM, MariettiM, HardyT, HenryL, EslamM, et al."/>
  <result pre="of liver disease among adults awaiting liver transplantation in the" exact="United States." post="Gastroenterology2015;148:547‐555.25461851 40YounossiZ, AnsteeQM, MariettiM, HardyT, HenryL, EslamM, et al."/>
  <result pre="of the most common causes of chronic liver diseases in" exact="the United States" post="from 1988 to 2008. Clin Gastroenterol Hepatol2011;9:524‐530.e521.21440669 42SugimotoR, IwasaM,"/>
  <result pre="the most common causes of chronic liver diseases in the" exact="United States" post="from 1988 to 2008. Clin Gastroenterol Hepatol2011;9:524‐530.e521.21440669 42SugimotoR, IwasaM,"/>
  <result pre="Prevalence of hepatitis B and hepatitis D virus infections in" exact="the United States," post="2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA, NiY, UrbanS. Hepatitis delta"/>
  <result pre="of hepatitis B and hepatitis D virus infections in the" exact="United States," post="2011‐2016. Clin Infect Dis2019;69:709‐712.30605508 69LemppFA, NiY, UrbanS. Hepatitis delta"/>
 </snippets>
</snippetsTree>
